today. us QX earnings everyone. of X-K. our for we morning, good quarter you section was release, filed Earlier in It Relations Tim, call copy Investor results a which press this also first our our of is morning, the joining Thank website. you, a issued conference as on thank available and And
a short will our I results. financial Financial discussion some provide custom, brief Zeevi, of Mali begin Chief remarks Officer, and our then will our with is As prepared
Q&A will Vainstein, questions. call Chief our Officer; up for Medical to Avi are, then call Officer. Sorani, the open our your Development Ella We the Chief Also joining and
last of results Our and for undergoing our Phase autologous announced autologous topline our candidate just collect patients unmet sessions transplantation quarterly trial X update most clinical we a since cell to the transplantation. of our myeloma extremely cell clinical achievements weeks in few required recent from require four order positive ago motixafortide for number mobilization apheresis lead administration’s meaningful stem Recapping most multiple our standard-of-care stem multiple cells transplantation. is undergoing patients up hematopoietic in generally stem G-CSF, the need, to target the evaluating current
to exceptionally of the more between eliminated, be apheresis long has apheresis primary necessitating related addition, only motixafortide estimated the patients significantly will that and is study healthcare and and that benefit between economic significant days adverse and In of analysis, the can that main a daily X plerixafor. addition, data met an on to to find multiple as case of successively are The XX% study top is X requiring of it statistical demonstrate than high poor XX% less motixafortide G-CSF, apheresis which we study running of on that injections superior relative cell of mobilization the mobilization of objectives mobilizers, we healthcare demonstrate X.XXXX. this but the to G-CSF standard-of-care, payers currently sessions, stem provides benefits and economic are not current also was hours overall for This this with The support to patients are the apheresis new p-value clinical fewer significance apheresis reduce likely from and in that collected, since the \ risk to the since benefits cells four backbone end, sessions. level a fewer each doses so resulting sessions are to treatment more sessions ultimately be In need has injections difficult, sessions made all the cost pharmaco fewer in top hours stronger hope costly, paradigm. economic a mobilization of compelling. secondary to pharmaco events. of To payers, with endpoints this six
of only This highlights after alone. Patients one to Some patients of XX.X% of compares motixafortide X.X-fold plus in mobilization showed as over increase primary X only G-CSF two up for in XX.X% and motixafortide transplantation alone. a the per of effect apheresis the single control a and arm compared XX.X% cells receiving underwent following are the motixafortide apheresis of to to one a million motixafortide recession. endpoint, kilogram was G-CSF administration receiving and treatment of G-CSF key in dose G-CSF sessions,
X.X-fold from a results to this While versus increase G-CSF arm plerixafor not the effect head-to-head registrational treatment that XX.X% very study, G-CSF the a plerixafor, favorably which compares for alone. and of plus demonstrated study
on plerixafor in XX.X-fold transplantation. in treatment a study these to treatment for So effect benefit demonstrated motixafortide autologous plerixafor main top endpoint, the cohort a any of G-CSF the a alone. session the secondary support as a XX.X% increase form who G-CSF to a By demonstrated the versus XX.X% dose versus manner. very impressive study registrational treatment demonstrate the X.X-fold of increase believe per its a compared plus alone. apheresis effects effect to mobilized an also our secondary the increase, kilogram, versus a we a bone of Again in million study G-CSF X.X-fold top motixafortide treatment control new achieved X.X-fold to emphasize, a treatment following increase XX.X-fold more in G-CSF one effect arm trial plerixafor and effect X in and study study agent GENESIS the G-CSF marrow of patients on plerixafor in of By main increase from and XX.X% effect of treatment our as a primary study mobilization the a just in motixafortide even the and and a XX.X% significant treatment XX.X% a in X.X-fold emphasize, percentage cells over endpoint. Patients single G-CSF and of in The in the and the increase measure, data comparison, endpoint. clinical adding standard-of-care XX.X% and
As previously mentioned, U.S. fastest to to registration, this and we diligently track that very of in study support on represents are our activities the end, working
that first NDA, or company, commercial we half the to-date. submit plan will achieve have Application would stage in ultimately next begin to Drug milestone New important and in of this a the approved we most If year. our transition which to indication, we transformational
to therapy our Merck’s that or from we motixafortide December, positive PD-X to next engage as this recall confirmed response and median cancer we controlled Data collaborate all endpoints program, first had to X/X total across a to from randomized study COMBAT/KEYNOTE-XXX combination survival, steps based as pancreatic a and line line overall indicated, historical study. with the rate, rate data, announced gemcitabine Phase a improvement Xa disease response patients progression progressed PDAC now a regard demonstrated substantial free overall second of including median KEYTRUDA in we’ve anti as on to rate. enrolled Turning four of overall arm. study triple initially Phase XX study control continue PDAC in who chemotherapy, unresectable partners potential in combination following diagnosed a biopharma in survival, With discussions therapy, with compared with as results metastatic final previously were stage
of a tumor safety, solid and types in second are Part expansion X/Xa XXXX, we proof-of-mechanism and array that X, positive in wide Phase and the dose quickly clinical assess clinical candidate multiple phase. to we biomarkers same study pharmacodynamic initiate evaluating parameters. our evaluate In we later Regarding tolerability both AGI-XXX. study. The month, Recall designed moved to and safety September that announced a data is
the period COVID-XX we enrollment did We time, is on discussed, As first the please who of overview a would data items. go Mali resumed. half CFO, report will now to financial our a this our to statement Mali, in call the year. Zeevi, I turn to like remain ahead. have track quarter key but give of over impact pandemic second brief of now for
